3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Vascular Diseases
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pathologic Processes
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphoid Interstitial Pneumonia
1
Lymphatic Diseases
1
Lung Neoplasms
1
Lung Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Lip Neoplasms
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Interventions
Cyclophosphamide
62
Dexamethasone
60
Melphalan
54
Peripheral Blood Stem Cell Transplantation
49
Bortezomib
40
Busulfan
39
fludarabine phosphate
34
Filgrastim
32
Lenalidomide
30
Thalidomide
27
Tacrolimus
25
Antilymphocyte Serum
23
Radiotherapy
22
Mycophenolic Acid
17
Methotrexate
17
Prednisone
15
Etoposide
15
sargramostim
14
Cyclosporine
14
fludarabine
12
Methylprednisolone
11
Granulocyte Colony-Stimulating Factor
11
Calcium Dobesilate
11
Whole-Body Irradiation
10
Doxorubicin
9
Carmustine
9
pomalidomide
8
Vincristine
8
Interferon-alpha
8
Cord Blood Stem Cell Transplantation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Plasma Cell
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled